Trial Profile
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Capecitabine
- Indications Adenocarcinoma; Carcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jul 2021 Status changed from active, no longer recruiting to completed.
- 09 Feb 2021 Planned End Date changed from 1 Jan 2021 to 1 Jun 2021.
- 03 Jul 2020 Planned End Date changed from 1 Apr 2019 to 1 Jan 2021.